An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts-Reference-Cited by-同舟云学术

An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts

Published:2017-01-03 Issue:1 Volume:12 Page:e0168960
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Chen Qing,Weng Ziyi,Lu Yunshu,Jia Yijun,Ding Longlong,Bai Fang,Ge Meixin,Lin Qing,Wu Kejin

Funder

Science and Technology Commission of Shanghai Municipality

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference49 articles.

1. Co-targeting estrogen receptor and HER2 pathways in breast cancer;A Mehta;Breast,2014

2. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers;JL Parra-Palau;Cancer Res,2010

3. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial;SA Hurvitz;Lancet Oncol,2015

4. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer;IE Krop;J Clin Oncol,2015

5. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;DJ Slamon;Science,1987

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab-conjugated liposomes for co-delivery of paclitaxel and anti-abcb1 siRNA in HER2-positive breast cancer: In vitro and in vivo evaluations;Journal of Drug Delivery Science and Technology;2024-05

2. Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG;Scientific Reports;2023-03-28

3. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells;Cancer Letters;2021-10

4. Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9);Breast Cancer Research and Treatment;2021-08-27

5. Evaluation the synergistic antitumor effect of methotrexate–camptothecin codelivery prodrug from self‐assembly process to acid‐catalyzed both drugs release: A comprehensive theoretical study;Journal of Computational Chemistry;2020-03-19